Vir Biotechnology Inc. fell almost 30% in its trading debut, adding to a series of IPO disappointments in an industry that was seen as at least partly immune to the ills afflicting this year’s newly public tech giants.
San Francisco-based Vir sold 7.14 million shares Thursday for $20 each -- the bottom of its marketed range -- to raise $143 million. The shares opened Friday at $16.15 and fell from there, closing at $14.02 to give the company a market value of about $1.5 billion.
